|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1995-5-5
|
|
pubmed:abstractText |
A vaccine consisting of purified Escherichia coli-expressed recombinant full-length outer surface proteins A (OspA) and B (OspB) and the saponin adjuvant QS21 was evaluated for protection against Borrelia burgdorferi infection. Eleven beagles were vaccinated twice and then challenged with 10 field-collected adult female Ixodes scapularis. Xenodiagnosis revealed that all 11 nonvaccinated control dogs and 2 of 10 vaccinated dogs were infected with B. burgdorferi. Six of 11 control dogs also developed fever (0.75 +/- 0.38 degrees C) and were lethargic. One of the control dogs also developed a limp. Both of the infected vaccinated dogs were asymptomatic. Thus, the vaccine prevented tick-vectored infection and associated symptoms of Lyme disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Outer Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/OspA protein,
http://linkedlifedata.com/resource/pubmed/chemical/OspB protein, Borrelia burgdorferi,
http://linkedlifedata.com/resource/pubmed/chemical/QS 21,
http://linkedlifedata.com/resource/pubmed/chemical/Saponins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
171
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1049-52
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7706788-Adjuvants, Immunologic,
pubmed-meshheading:7706788-Animals,
pubmed-meshheading:7706788-Antibodies, Bacterial,
pubmed-meshheading:7706788-Antigens, Bacterial,
pubmed-meshheading:7706788-Antigens, Surface,
pubmed-meshheading:7706788-Bacterial Outer Membrane Proteins,
pubmed-meshheading:7706788-Bacterial Vaccines,
pubmed-meshheading:7706788-Borrelia burgdorferi Group,
pubmed-meshheading:7706788-Dogs,
pubmed-meshheading:7706788-Female,
pubmed-meshheading:7706788-Immunoglobulin G,
pubmed-meshheading:7706788-Lipoproteins,
pubmed-meshheading:7706788-Lyme Disease,
pubmed-meshheading:7706788-Male,
pubmed-meshheading:7706788-Saponins,
pubmed-meshheading:7706788-Ticks,
pubmed-meshheading:7706788-Vaccination,
pubmed-meshheading:7706788-Vaccines, Synthetic
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
|
|
pubmed:affiliation |
Cambridge Biotech Corp., Worcester, Massachusetts 01605.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
